ATE437637T1 - Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren - Google Patents
Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahrenInfo
- Publication number
- ATE437637T1 ATE437637T1 AT02766876T AT02766876T ATE437637T1 AT E437637 T1 ATE437637 T1 AT E437637T1 AT 02766876 T AT02766876 T AT 02766876T AT 02766876 T AT02766876 T AT 02766876T AT E437637 T1 ATE437637 T1 AT E437637T1
- Authority
- AT
- Austria
- Prior art keywords
- nitric oxide
- treating
- pharmaceutically acceptable
- acceptable salt
- compositions
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229960000619 nebivolol Drugs 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 7
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000002840 nitric oxide donor Substances 0.000 abstract 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 abstract 1
- 229960002474 hydralazine Drugs 0.000 abstract 1
- -1 hydralazine compound Chemical class 0.000 abstract 1
- RPTUSVTUFVMDQK-UHFFFAOYSA-N hydrallazine Natural products C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 abstract 1
- 229960000201 isosorbide dinitrate Drugs 0.000 abstract 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 abstract 1
- 229960003827 isosorbide mononitrate Drugs 0.000 abstract 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28772501P | 2001-05-02 | 2001-05-02 | |
| PCT/US2002/013667 WO2002087508A2 (en) | 2001-05-02 | 2002-05-01 | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437637T1 true ATE437637T1 (de) | 2009-08-15 |
Family
ID=23104065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02766876T ATE437637T1 (de) | 2001-05-02 | 2002-05-01 | Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7138430B2 (de) |
| EP (1) | EP1406608B1 (de) |
| JP (2) | JP2004528337A (de) |
| AT (1) | ATE437637T1 (de) |
| AU (1) | AU2002338528B2 (de) |
| CA (1) | CA2446064A1 (de) |
| DE (1) | DE60233140D1 (de) |
| WO (1) | WO2002087508A2 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| JP2007502831A (ja) * | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法 |
| US7754500B2 (en) | 2003-11-21 | 2010-07-13 | Anp Technologies, Inc. | Asymmetrically branched polymer conjugates and microarray assays |
| US20090131342A1 (en) * | 2004-01-22 | 2009-05-21 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
| WO2005102304A1 (en) * | 2004-04-23 | 2005-11-03 | Northern Sydney And Central Coast Area Health Service | Methods and compositions for the treatment of myocardial conditions |
| US7838552B2 (en) * | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| WO2005118166A2 (en) | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
| WO2006025070A2 (en) | 2004-07-30 | 2006-03-09 | Torrent Pharmaceuticals Limited | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol |
| CA2576255A1 (en) * | 2004-08-09 | 2006-02-16 | Universite Catholique De Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| NZ560386A (en) * | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| WO2006083780A2 (en) * | 2005-01-31 | 2006-08-10 | Mylan Laboratories, Inc. | Glucuronidated nebivolol |
| US20060222592A1 (en) * | 2005-04-05 | 2006-10-05 | Clemens Burda | Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications |
| CA2606815C (en) | 2005-05-02 | 2017-03-07 | Anp Technologies, Inc. | Polymer conjugate enhanced bioassays |
| NZ563759A (en) * | 2005-05-31 | 2010-06-25 | Mylan Lab Inc | Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate |
| RU2441653C2 (ru) * | 2005-05-31 | 2012-02-10 | Милан Лэборетериз, Инк. | Композиции, содержащие небиволол |
| US20090253662A1 (en) * | 2005-10-04 | 2009-10-08 | Nitromed, Inc. | Genetic risk assessment in heart failure: impact of genetic variation of aldosterone synthase promoter polymorphism |
| US20070154466A1 (en) * | 2005-12-30 | 2007-07-05 | Jan Weber | Internal medical devices containing peroxide-converting catalysts |
| US20080193385A1 (en) * | 2007-02-08 | 2008-08-14 | Todd Maibach | Compositions and methods for treating neuropathy |
| CA2599082A1 (en) * | 2007-08-27 | 2009-02-27 | Ping I. Lee | Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds |
| WO2009026697A1 (en) * | 2007-08-28 | 2009-03-05 | University Of Manitoba | A method of reducing a vasodilatory response using a guanylate cyclase pathway inhibitor or an h2o2 reducing agent |
| TW200918099A (en) | 2007-09-14 | 2009-05-01 | Nitto Denko Corp | Drug carriers |
| CA2732513C (en) | 2008-08-01 | 2017-04-25 | Arca Biopharma, Inc. | Methods and compositions involving (s)-bucindolol |
| HUP0800498A2 (en) * | 2008-08-06 | 2010-03-29 | Semmelweis Egyetem | Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level |
| US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
| US11207109B2 (en) | 2010-10-20 | 2021-12-28 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
| US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
| US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
| CN102977068A (zh) * | 2012-05-03 | 2013-03-20 | 中国药科大学 | 一氧化氮供体型异色满酮类衍生物、其制备方法及用途 |
| US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
| EP2946213B1 (de) * | 2013-01-18 | 2023-05-24 | synlab Services GmbH | Vorhersage des fortschreitens einer nierenerkrankung unter verwendung von homoarginin als biomarker |
| US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
| JP7002451B2 (ja) | 2015-12-15 | 2022-01-20 | ニオバスク ティアラ インコーポレイテッド | 経中隔送達システム |
| CN108882981B (zh) | 2016-01-29 | 2021-08-10 | 内奥瓦斯克迪亚拉公司 | 用于防止流出阻塞的假体瓣膜 |
| US11173235B2 (en) | 2016-07-15 | 2021-11-16 | Cook Regentec Llc | Nitrite eluting devices and methods of use thereof |
| US11096781B2 (en) | 2016-08-01 | 2021-08-24 | Edwards Lifesciences Corporation | Prosthetic heart valve |
| CN110198728A (zh) | 2016-11-17 | 2019-09-03 | 莱诺翁股份有限公司 | 用谷胱甘肽组合物治疗呼吸道疾病和感染 |
| AU2017361296B2 (en) | 2016-11-21 | 2022-09-29 | Neovasc Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
| EP3672530A4 (de) | 2017-08-25 | 2021-04-14 | Neovasc Tiara Inc. | Sequentiell eingesetzte transkatheter-mitralklappenprothese |
| CN111615395B (zh) | 2017-11-17 | 2024-08-06 | 莱诺翁股份有限公司 | 稳定的抗坏血酸组合物及其使用方法 |
| US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
| MX2020012717A (es) | 2018-05-25 | 2021-07-15 | Arca Biopharma Inc | Métodos y composiciones con bucindolol para el tratamiento de la fibrilación auricular. |
| AU2019374743B2 (en) | 2018-11-08 | 2022-03-03 | Neovasc Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
| CN113747863B (zh) | 2019-03-08 | 2024-11-08 | 内奥瓦斯克迪亚拉公司 | 可取回假体递送系统 |
| AU2020256195B2 (en) | 2019-04-01 | 2022-10-13 | Neovasc Inc. | Controllably deployable prosthetic valve |
| US11491006B2 (en) | 2019-04-10 | 2022-11-08 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
| CA3282225A1 (en) | 2019-05-20 | 2026-03-02 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
| JP7520897B2 (ja) | 2019-06-20 | 2024-07-23 | ニオバスク ティアラ インコーポレイテッド | 薄型人工補綴僧帽弁 |
| CA3199943A1 (en) | 2020-08-24 | 2022-03-03 | Edwards Lifesciences Corporation | Balloon cover for a delivery apparatus for an expandable prosthetic heart valve |
| WO2022198259A1 (en) * | 2021-03-25 | 2022-09-29 | The Heart Research Institute Ltd | Treatment methods for pulmonary arterial hypertension |
| KR20240131358A (ko) | 2022-01-04 | 2024-08-30 | 레노비온, 아이엔씨. | 글루타치온 염을 포함하는 수용액 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US311175A (en) | 1885-01-27 | And joseph l | ||
| US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
| CA1337429C (en) | 1983-12-05 | 1995-10-24 | Guy Rosalia Eugene Van Lommen | Derivatives of 2,2'-iminobisethanol |
| US4868179A (en) | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
| CA1337432C (en) | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
| US5428061A (en) | 1988-09-15 | 1995-06-27 | Schwarz Pharma Ag | Organic nitrates and method for their preparation |
| US5284872A (en) | 1989-09-12 | 1994-02-08 | Schwarz Pharma Ag | Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof |
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| DK0676964T3 (da) | 1991-11-14 | 2001-02-05 | Brigham & Womens Hospital | Nitrosylering af enzym-SH-grupper som en terapeutisk modalitet |
| US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| DE4321306A1 (de) | 1993-06-26 | 1995-01-05 | Sanol Arznei Schwarz Gmbh | Disulfide |
| TW355683B (en) | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
| HU226208B1 (en) | 1994-12-28 | 2008-06-30 | Janssen Pharmaceutica Nv | Use of nebivolol for producing anti-atherogenic pharmaceuticals |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5932538A (en) | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
| US5807847A (en) | 1996-06-04 | 1998-09-15 | Queen's University At Kingston | Nitrate esters |
| CA2270118A1 (en) | 1996-11-01 | 1998-05-14 | Nitromed Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| IT1292426B1 (it) | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| EP1000023B1 (de) | 1997-07-03 | 2011-02-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Stickoxid freistetzende amidin- und enaminverwandte diazeniumdiolate, zubereitungen und verwendungen davon und verfahren zu ihrer herstellung |
| IT1301759B1 (it) | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
| AU3713600A (en) | 1999-03-01 | 2000-09-21 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
| IT1308633B1 (it) | 1999-03-02 | 2002-01-09 | Nicox Sa | Nitrossiderivati. |
| IT1311924B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IT1311921B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IT1311923B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| IT1314184B1 (it) * | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| US6635273B1 (en) * | 1999-10-29 | 2003-10-21 | Trustees Of Boston University | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| IT1320176B1 (it) | 2000-12-22 | 2003-11-26 | Nicox Sa | Dispersioni solide di principi attivi nitrati. |
| JP2007513113A (ja) | 2003-12-02 | 2007-05-24 | ニコックス エス エイ | 抗高血圧薬剤のニトロオキシ誘導体 |
| DK1691804T3 (da) | 2003-12-02 | 2007-07-16 | Nicox Sa | Nitrooxydderivater af carvedilol og andre beta-blokkere som antihypertensive lægemidler |
-
2002
- 2002-05-01 AT AT02766876T patent/ATE437637T1/de not_active IP Right Cessation
- 2002-05-01 CA CA002446064A patent/CA2446064A1/en not_active Abandoned
- 2002-05-01 JP JP2002584860A patent/JP2004528337A/ja not_active Withdrawn
- 2002-05-01 DE DE60233140T patent/DE60233140D1/de not_active Expired - Lifetime
- 2002-05-01 EP EP02766876A patent/EP1406608B1/de not_active Expired - Lifetime
- 2002-05-01 AU AU2002338528A patent/AU2002338528B2/en not_active Ceased
- 2002-05-01 WO PCT/US2002/013667 patent/WO2002087508A2/en not_active Ceased
-
2003
- 2003-10-29 US US10/695,644 patent/US7138430B2/en not_active Expired - Fee Related
-
2005
- 2005-07-13 US US11/135,418 patent/US7384976B2/en not_active Expired - Fee Related
-
2010
- 2010-06-25 JP JP2010145153A patent/JP2010248226A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1406608A4 (de) | 2004-10-20 |
| EP1406608A2 (de) | 2004-04-14 |
| US20040132805A1 (en) | 2004-07-08 |
| JP2010248226A (ja) | 2010-11-04 |
| US7138430B2 (en) | 2006-11-21 |
| WO2002087508A3 (en) | 2003-12-11 |
| WO2002087508A2 (en) | 2002-11-07 |
| US20060009513A1 (en) | 2006-01-12 |
| US7384976B2 (en) | 2008-06-10 |
| JP2004528337A (ja) | 2004-09-16 |
| DE60233140D1 (de) | 2009-09-10 |
| EP1406608B1 (de) | 2009-07-29 |
| CA2446064A1 (en) | 2002-11-07 |
| AU2002338528B2 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60233140D1 (de) | Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren | |
| UA84420C2 (ru) | СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК | |
| BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| BRPI0412659A (pt) | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto | |
| UY28314A1 (es) | Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
| NO20055219L (no) | Nye forbindelser | |
| ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
| SE9800836D0 (sv) | New Compounds | |
| SE0300119D0 (sv) | Novel compounds | |
| GB0112348D0 (en) | Compounds | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
| EE200400031A (et) | Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat | |
| BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| DE60129829D1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| CY1108224T1 (el) | Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα | |
| NO995431L (no) | Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse | |
| ATE417856T1 (de) | Motilidverbindungen | |
| WO2004002420A3 (en) | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use | |
| IL166103A0 (en) | Pyrrolidine derivatives and their use | |
| BR0312183A (pt) | Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica | |
| ATE265423T1 (de) | Neue phenylheteroalkylamin-derivate | |
| DE60210981D1 (de) | Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase | |
| DE69402004D1 (de) | Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen | |
| EA200700979A1 (ru) | Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |